NNC0363-0845

NNC0363-0845 is a synthetic peptide drug candidate developed by Novo Nordisk for the treatment of diabetes, specifically type 1 and type 2 diabetes. It is designed as a glucose-sensitive insulin, meaning it aims to release or activate insulin in response to plasma or interstitial glucose levels, potentially improving glycemic control and reducing the risk of hypoglycemia compared to conventional insulins. The mechanism of action involves agonism at the insulin receptor (INSR), mimicking endogenous insulin activity. NNC0363-0845 has completed initial phase 1 clinical trials in healthy volunteers and people with type 1 diabetes, where its safety, tolerability, pharmacokinetics, and blood sugar-lowering effects were evaluated[1][2][3][4][5].

Other names

glucose-sensitive insulin